Clinical Trials Logo

Clinical Trial Summary

To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate. However, as the study sample size was 40, the investigators need to validate the tumor response rate using a larger sample size; To validate the overall survival: in the previous study, the investigators showed that TILA-TACE significantly prolonged the overall survival of the patients with large and massive tumor. Again, the sample size was small, the investigators need to validate the data using a large sample size.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03910140
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact
Status Recruiting
Phase N/A
Start date November 1, 2017
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04025840 - Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Phase 4
Completed NCT04111926 - Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery Phase 4
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Completed NCT03923400 - Jejunoileal vs Gastric GIST in the Era of Imatinib.
Withdrawn NCT02201381 - Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Phase 3
Recruiting NCT05392257 - Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial Phase 2
Recruiting NCT05310357 - Chromosomal Instability in Ovarian Cancer
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Active, not recruiting NCT04245644 - Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
Recruiting NCT04245410 - Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
Completed NCT02980185 - Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer N/A
Recruiting NCT03967457 - Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Recruiting NCT04050787 - Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Completed NCT03726021 - Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT02942238 - Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC) N/A
Not yet recruiting NCT01236989 - Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC N/A
Recruiting NCT05218629 - Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer Phase 2